- Design
- Narrative review, non-systematic search
- Population
- Published preclinical and human studies of GLP-1 RA exposure from preconception to postpartum
- Primary outcome
- Anomalies, hypertensive disorders, gestational diabetes, preterm birth, fetal growth, stillbirth
- Effect
- No clear increase in adverse outcomes reported; evidence limited by size and design
A BJOG narrative review gathered the preclinical work, observational pregnancy cohorts and pharmacokinetic data on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) taken shortly before or in early pregnancy. It was a non-systematic search, so it summarises the field rather than pooling it.
The human data so far have not shown a clear rise in congenital anomalies, hypertensive disorders, gestational diabetes, preterm birth, growth problems or stillbirth after periconception exposure. The authors are explicit that this is not reassurance: the studies are small, observational, open to confounding by obesity and diabetes, and often miss exposures altogether.
The practical problem is growing. These drugs are widely used by women of reproductive age, may restore ovulation in women with obesity or polycystic ovary syndrome, and routine booking questions often do not ask about them.
For the clinic: ask about GLP-1 RAs at booking and preconception visits, record the agent and the date of the last dose, and counsel on the actual evidence. Neither termination on safety grounds nor blanket reassurance is supported.
- Ask every woman at booking whether she has taken a GLP-1 receptor agonist in the past few months, including drugs bought for weight loss.
- Record the agent, dose and date of last injection, since washout periods differ between weekly and daily drugs.
- Counsel exposed women that current observational data show no clear signal of harm but cannot rule one out.
- Women starting these drugs who could conceive need a contraception discussion, as ovulation may return with weight loss.
- Consider reporting exposed pregnancies to a pregnancy registry where one exists, as that is how the evidence will grow.
Why it matters
Inadvertent exposure is becoming routine, and most booking histories still do not capture it.
Don't overread it
This was a narrative review of observational data; the absence of a signal is not evidence of safety.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free